The FDA has approved Jazz Pharmaceuticals' Zepzelca and Roche's Tecentriq combination as the first and only first-line maintenance treatment for extensive-stage small cell lung cancer. This approval, based on trial data showing reduced disease progression and death risk, offers a new option for this aggressive cancer, making the therapy eligible for reimbursement.